- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00705926
Effectiveness of Antiretroviral Therapy During Acute HIV Infection
A Phase 1 Clinical Trial to Evaluate the Initiation of Treatment Versus no Treatment During Acute HIV-1 Infection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Antiretroviral (ARV) therapy for the treatment of HIV infection has been remarkably successful in reducing morbidity and mortality in HIV infected people. This treatment still has its shortcomings, however. Individuals receiving ARV treatment are at risk of toxicity, developing drug resistance, and unknown long-term side effects. Therefore, development of alternative treatment strategies is important. A short course of ARV treatment that is initiated during the acute period of HIV infection, followed by treatment cessation may have a substantial impact on controlling infection and delaying the need for lifelong potent ARV therapy. The purpose of this study is to investigate whether treatment initiated during acute HIV infection and followed by a terminal treatment interruption is effective in lowering the viral load set point and raising CD4 cell counts in people with HIV, as compared to those measures in people with HIV who have received no treatment.
Participants in this study will be randomly assigned to one of three groups. Participants in Group A1 will receive ARV therapy for 12 weeks. Participants in Group A2 will receive ARV therapy for 32 weeks. Participants in Group B will not receive any treatment. This study will not provide medications to any of the groups. All groups will be followed for a total of 72 weeks following study entry. Participants will attend between 30 and 36 study visits over the course of the 72 weeks, depending on their study group. Study visits will occur every week for the first 12 weeks and then every 1 to 6 weeks for the remainder of the study. Tests occurring at study visits may include blood tests, investigational immune system tests, and pregnancy tests. Participants will also undergo a complete physical exam and will be asked to provide information about their medical and medication histories.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Acute HIV infection as determined by a positive HIV viral load (at least 5,000 copies of RNA per ml of plasma) and a negative or indeterminate Western Blot test
- Certain laboratory values. More information about this criterion can be found in the protocol.
- Agrees to use an approved form of contraception
Exclusion Criteria:
- Presence of opportunistic infections or AIDS-defining illnesses, unless they are directly attributable to the acute seroconversion illness
- Receipt of investigational research agents within 30 days prior to study entry
- Receipt of prior experimental HIV vaccines. Individuals who received a saline placebo in a prior HIV vaccine trial are not excluded, provided that they did not receive a sham vector or an adjuvant.
- Receipt of immunosuppressive medications or immunomodulators (e.g., cytokine therapy) within the past 6 months. Participants taking corticosteroid nasal spray for allergic rhinitis; topical corticosteroids for acute, uncomplicated dermatitis; or over the counter medications for acute, uncomplicated dermatitis for a period not longer than 14 days will not be excluded.
- Current use of prohibited concomitant medications
- Current anti-tuberculosis prophylaxis or therapy
- Serious illness other than acute HIV infection requiring systemic treatment or hospitalization until either therapy is completed or patient is clinically stable on therapy
- Hepatitis B surface antigen positivity within 21 days prior to study entry
- Pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A1
Antiretroviral therapy followed by discontinuation at Week 12.
|
Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks.
Their medications will not be provided by the study.
|
Experimental: A2
Antiretroviral therapy followed by discontinuation at Week 32.
|
Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks.
Their medications will not be provided by the study.
|
Placebo Comparator: B
No treatment.
|
Participants in this group will not receive treatment at this stage of their infection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in the level of HIV RNA at viral load set point if therapy is initiated during acute HIV infection followed by terminal treatment interruption after 12 or 32 weeks of treatment compared to that under no treatment
Time Frame: Week 72
|
Week 72
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in the level of CD4 cells if therapy is initiated during acute HIV infection followed by terminal treatment interruption after 12 or 32 weeks of treatment compared to that under no treatment
Time Frame: Week 72
|
Week 72
|
Difference in the level of HIV RNA and CD4 cell numbers between therapy initiated during acute HIV infection followed by terminal treatment interruption after at least 12 weeks of treatment and no therapy at 16 weeks after discontinuation of treatment
Time Frame: Weeks 12 and 16
|
Weeks 12 and 16
|
Difference in the level of HIV at viral load set point and CD4 cell number at 72 weeks after study entry if therapy is initiated during acute HIV infection followed by terminal treatment interruption at 12 weeks versus at 32 weeks
Time Frame: Week 72
|
Week 72
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Eric S. Rosenberg, MD, Massachusetts General Hospital, Division of Infectious Diseases
- Principal Investigator: H.T. Banks, PhD, North Carolina State University, College of Physical and Mathematical Sciences
- Principal Investigator: Marie Davidian, PhD, North Carolina State University, Department of Statistics
Publications and helpful links
General Publications
- Kassutto S, Rosenberg ES. Primary HIV type 1 infection. Clin Infect Dis. 2004 May 15;38(10):1447-53. doi: 10.1086/420745. Epub 2004 Apr 30.
- Kassutto S, Maghsoudi K, Johnston MN, Robbins GK, Burgett NC, Sax PE, Cohen D, Pae E, Davis B, Zachary K, Basgoz N, D'agata EM, DeGruttola V, Walker BD, Rosenberg ES. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis. 2006 Apr 1;42(7):1024-31. doi: 10.1086/500410. Epub 2006 Feb 27.
- Kassutto S, Rosenberg ES. Editorial comment: treatment of acute HIV infection--uncertainties about best practice. AIDS Read. 2005 May;15(5):250-1. No abstract available.
- Lacabaratz-Porret C, Urrutia A, Doisne JM, Goujard C, Deveau C, Dalod M, Meyer L, Rouzioux C, Delfraissy JF, Venet A, Sinet M. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Infect Dis. 2003 Mar 1;187(5):748-57. doi: 10.1086/368333. Epub 2003 Feb 18.
- Malhotra U, Berrey MM, Huang Y, Markee J, Brown DJ, Ap S, Musey L, Schacker T, Corey L, McElrath MJ. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis. 2000 Jan;181(1):121-31. doi: 10.1086/315202.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Disease Attributes
- Slow Virus Diseases
- HIV Infections
- Infections
- Communicable Diseases
- Acquired Immunodeficiency Syndrome
- Anti-Infective Agents
- Antiviral Agents
- Anti-Retroviral Agents
Other Study ID Numbers
- R01AI071915 (U.S. NIH Grant/Contract)
- RO1AIO71915 (Other Grant/Funding Number: NIAID)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Highly Active Antiretroviral Therapy (HAART)
-
Johns Hopkins Bloomberg School of Public HealthNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
International Maternal Pediatric Adolescent AIDS...National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy...CompletedHIV InfectionUnited States, Argentina, Botswana, Brazil, China, Haiti, Peru, Puerto Rico, Thailand
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | Hepatitis CUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Dutch AIDS FundTerminated
-
University of ZimbabweUniversity Hospital Inselspital, Berne; University of Oxford; Wellcome Trust; University... and other collaboratorsUnknownHIV Infections | Immune Activation | Comorbidities
-
Genetic ImmunityCompleted
-
Genetic ImmunityIRCCS Policlinico S. Matteo; ViroStatics srlCompleted
-
Hoffmann-La RocheCompletedHIV InfectionsFrance, Germany, Spain, Italy, United States, Switzerland, Netherlands, Mexico, Canada, Israel
-
Rajavithi HospitalRajavithi Biomolecular Research CenterCompleted
-
International Maternal Pediatric Adolescent AIDS...National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy...TerminatedHIV DiseaseUnited States, Puerto Rico, Argentina, Brazil, Thailand